Galcanezumab, Placebo to match LY2951742
I5Q-MC-CGAS
Phase 3 small_molecule active
Quick answer
Galcanezumab, Placebo to match LY2951742 for Migraine is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Migraine
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active